Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 6/2015

01-06-2015 | 2014 SSAT Plenary Presentation

Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging

Authors: Simon Lavotshkin, John R. Jalas, Hitoe Torisu-Itakura, Junko Ozao-Choy, Ji Hey Lee, Myung Shin Sim, Alexander Stojadinovic, Zev Wainberg, Carlo B. Bifulco, Bernard A. Fox, Anton J. Bilchik

Published in: Journal of Gastrointestinal Surgery | Issue 6/2015

Login to get access

Abstract

Background

Although AJCC/TNM staging remains the gold standard for prognostic assessment of colon cancer, stage-specific outcomes vary. We therefore prospectively evaluated the prognostic role of immunoprofiling.

Methods

Our cohort included 35 patients from an ongoing prospective trial of ultrastaging for colon cancer. Specimens were analyzed for T cell markers (CD3, CD4, CD8, and FoxP3). The number of tumor-infiltrating lymphocytes was analyzed at the tumor’s margin and center and correlated with AJCC/TNM stage, clinicopathologic variables, and disease-free survival.

Results

There was a significant inverse association between number of CD3+ cells in the tumor center and tumor stage (P = 0.05). The tumor center/margin ratio of CD3+ cells also showed an inverse but non-significant relationship with nodal involvement (P = 0.07). Body mass index was inversely associated with numbers of CD3+(P = 0.04) and CD8+(P = 0.02) cells. Longer disease-free survival was correlated with higher CD8+ counts (P = 0.07), lower CD4+/CD8+ ratios (P = 0.008), and higher CD8+/FoxP3+ ratios (P = 0.02).

Conclusions

This is the first prospective validation of immunoprofiling in patients whose colon cancer is staged with strict surgical and pathology quality measures. The apparent correlation between immunophenotypic response and clinical outcome warrants evaluation in a larger prospective trial.
Literature
1.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298: 850–4.CrossRefPubMedCentralPubMed
2.
Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Annals of surgical oncology 2013;20: 3106–11.CrossRefPubMed
3.
Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. Journal of neurosurgery 2011;115: 505–11.CrossRefPubMed
4.
Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer research 2001;61: 5132–6.PubMed
5.
Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K. Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. British journal of cancer 2007;97: 1135–8.CrossRefPubMedCentralPubMed
6.
Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cellular & molecular immunology 2011;8: 59–66.CrossRef
7.
Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, Daniele L, Oliaro A. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. The Annals of thoracic surgery 2009;87: 365–71; discussion 71–2.CrossRefPubMed
8.
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24: 5373–80.CrossRef
9.
Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. American journal of clinical oncology 2013;36: 224–31.CrossRefPubMed
10.
Chen KJ, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. Medical oncology 2012;29: 1817–26.CrossRefPubMed
11.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313: 1960–4.CrossRefPubMed
12.
Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27: 5944–51.CrossRef
13.
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer research 1998;58: 3491–4.PubMed
14.
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. The New England journal of medicine 2005;353: 2654–66.CrossRefPubMed
15.
Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29: 610–8.CrossRef
16.
Bilchik A, Nissan A, Wainberg Z, Shen P, McCarter M, Protic M, Howard R, Elashoff D, Tyler J, Peoples GE, Stojadinovic A. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. Annals of surgery 2010;252: 467–74; discussion 74–6.PubMedCentralPubMed
17.
Bilchik AJ, Hoon DS, Saha S, Turner RR, Wiese D, DiNome M, Koyanagi K, McCarter M, Shen P, Iddings D, Chen SL, Gonzalez M, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Annals of surgery 2007;246: 568–75; discussion 75–7.CrossRefPubMed
18.
Quasar Collaborative G, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370: 2020–9.CrossRef
19.
Benson AB, 3rd, Hamilton SR. Path toward prognostication and prediction: an evolving matrix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29: 4599–601.CrossRef
20.
Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27: 3109–16.CrossRef
21.
Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28: 3219–26.CrossRef
22.
Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24: 4685–91.CrossRef
23.
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23: 3526–35.CrossRef
24.
Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29: 17–24.CrossRef
25.
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. The Journal of pathology 2014;232: 199–209.CrossRefPubMedCentralPubMed
26.
Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of translational medicine 2012;10: 205.CrossRefPubMedCentralPubMed
27.
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. The Journal of pathology 2010;222: 350–66.CrossRefPubMedCentralPubMed
28.
Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer immunology, immunotherapy : CII 2003;52: 423–8.CrossRefPubMed
29.
Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K, Aoki D. Immunofluorescence-detected infiltration of CD4 + FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21: 1628–34.CrossRef
30.
Kim HI, Kim H, Cho HW, Kim SY, Song KJ, Hyung WJ, Park CG, Kim CB. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. Journal of surgical oncology 2011;104: 728–33.CrossRefPubMed
31.
Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer immunology, immunotherapy : CII 2010;59: 653–61.CrossRefPubMed
32.
Edge SBB, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A., ed AJCC Cancer Staging Manual (ed 7th Edition). New York: Springer; 2010.
Metadata
Title
Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging
Authors
Simon Lavotshkin
John R. Jalas
Hitoe Torisu-Itakura
Junko Ozao-Choy
Ji Hey Lee
Myung Shin Sim
Alexander Stojadinovic
Zev Wainberg
Carlo B. Bifulco
Bernard A. Fox
Anton J. Bilchik
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 6/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2759-6

Other articles of this Issue 6/2015

Journal of Gastrointestinal Surgery 6/2015 Go to the issue

Case Report

Unusual Osseous Metastases from Rectal Adenocarcinoma: A Case Report and Review of the Literature

Original Article

Role of Laparoscopic Partial Splenectomy for Tumorous Lesions of the Spleen

Original Article

Chronic Abdominal Syndrome Due to Nervous Compression. Study of 100 Cases and Proposed Diagnostic-Therapeutic Algorithm

Original Article

Adherence to Guidelines for Adjuvant Imatinib Therapy for GIST: A Multi-institutional Analysis

2014 SSAT Plenary Presentation

Do Adverse Childhood Experiences Affect Surgical Weight Loss Outcomes?

Letter to the Editor

Goal-Directed Therapy for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: the Right Approach in the Right Place